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Purpose: The purpose of this study was to investigate the predictability of pretreat-
ment values including Dynamic Contrast-Enhanced Magnetic Resonance Imaging 
(DCE-MRI) derived parameters (Ktrans, Kep and Ve), early changes in parameters 
(Ktrans, tumor volume), and heterogeneity (standard deviation of Ktrans) for radiation 
therapy responses via a human colorectal cancer xenograft model. Materials and 
Methods: A human colorectal cancer xenograft model with DLD-1 cancer cells was 
produced in the right hind limbs of five mice. Tumors were irradiated with 3 frac-
tions of 3 Gy each for 3 weeks. Baseline and follow up DCE-MRI were performed. 
Quantitative parameters (Ktrans, Kep and Ve) were calculated based on the Tofts mod-
el. Early changes in Ktrans, standard deviation (SD) of Ktrans, and tumor volume were 
also calculated. Tumor responses were evaluated based on histology. With a cut-off 
value of 0.4 for necrotic factor, a comparison between good and poor responses was 
conducted. Results: The good response group (mice #1 and 2) exhibited higher pre-
treatment Ktrans than the poor response group (mice #3, 4, and 5). The good response 
group tended to show lower pretreatment Kep, higher pretreatment Ve, and larger 
baseline tumor volume than the poor response group. All the mice in the good re-
sponse group demonstrated marked reductions in Ktrans and SD value after the first 
radiation. All tumors showed increased volume after the first radiation therapy. Con-
clusion: The good response after radiation therapy group in the DLD-1 colon cancer 
xenograft nude mouse model exhibited a higher pretreatment Ktrans and showed an 
early reduction in Ktrans, demonstrating a more homogenous distribution.
Key Words:   Colorectal cancer, radiation therapy, magnetic resonance imaging, 
permeability, angiogenesis
INTRODUCTION
Colorectal cancer is a frequently diagnosed cancer with high mortality. In patients 
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tal cancer xenograft model.
MATERIALS AND METHODS
　　　
Experimental model
All experiments followed institutional guidelines for the 
care and use of laboratory animals. A human DLD-1 colon 
cancer cell suspension (1×106 cells in 100 µL of phosphate 
buffered saline) was implanted subcutaneously into the 
right hind limbs of five 5-week-old (SLC, Kotoh-cho, Ja-
pan) female nude mouse. Tumors were allowed to grow for 
approximately 7 to 14 days, until reaching an approximate 
longest diameter of 1 cm before initiating radiation therapy. 
However, there was some degree of variability in volume 
because the tumors in each mouse did not grow at exactly 
the same rate.
Irradiations
The mice were anesthetized by intraperitoneal injection of a 
mixture of Zoletil (40 mg/kg) and Rompun (5 mg/kg) to 
achieve reproducible prone positioning during treatment. 
Irradiations were performed with a linear accelerator 
(CGR, Paris, France) using a beam of 18-MV photons. The 
dose rate was 200 cGy/min at a focus-to-skin distance of 
127 cm. The hind leg subcutaneously implanted tumor was 
irradiated while the remainder of the mouse was shielded 
with 8-cm-thick Arplay Cerro (Arplay, Izeure, France), po-
sitioned on top of a 2.5-cm PlexiglasTM (Rohm and Haas 
company, Philadelphia, PA, USA) plate necessary for elec-
tronic equilibrium. Dosimetry in the treatment position was 
performed using LiF pastilles positioned at the area of tu-
mor cell inoculation to indicate accurate dose delivery to 
the tumor. Each mouse received 3 fractions of 3 Gy each 
for a total of 21 days at an interval of 7 days. After three cy-
cles of irradiations were completed, the nude mice were eu-
thanized.
MR examinations
DCE MRI was performed four times for each mouse. The 
first base line study was performed immediately before ini-
tiating radiation therapy. The other three MRIs were per-
formed one week after each radiation therapy.
Magnetic resonance imaging was performed using a 
whole-body 3T MR scanner (MAGNETOM Tim Trio, Sie-
mens Healthcare, Erlangen, Germany) and a four-phased ar-
ray wrist coil (Siemens Healthcare). The mice were placed 
with advanced stage, preoperative radiation therapy or pre-
operative concurrent chemo-radiation therapy (CCRT) is 
frequently administered.1-3 Such therapies are useful for de-
creasing rates of recurrence.4 However, there are currently 
no methods for predicting which tumors will respond to ra-
diation therapy.
Tumor vascularity and oxygenation status have long been 
advocated as important factors that influence tumor respons-
es to radiation therapy.5 Dynamic contrast-enhanced mag-
netic resonance imaging (DCE-MRI) combined with phar-
macokinetic modeling has emerged as a promising 
noninvasive imaging technique for evaluating tumor micro-
vasculature, generating quantitative parameters of microcir-
culation based on the two-compartment Tofts model.6,7 Ac-
cording to this model, contrast enters the intravascular space 
(compartment 1), passes into the interstitial space (compart-
ment 2), and reenters the intravascular space (compartment 
1). During this course, Ktrans represents the rate of which the 
contrast media passes from the intravascular space to the 
interstitial space. Kep signifies the rate constant for back dif-
fusion of the contrast agent from the interstitial space into 
the intravascular space. Ve denotes extravascular-extracel-
lular leakage space. Several studies have shown that DCE-
MRI derived parameters are related to tumor responses to 
treatment. George, et al.8 showed that responsive tumors 
had higher pretreatment Ktrans values than non-responsive 
tumors in colorectal cancer. In addition, Ah-See, et al.9 re-
cently reported that early changes in Ktrans are the best pre-
dictor for treatment responses to chemotherapy in patients 
with breast cancer. Meanwhile, Yu, et al.10 showed that ear-
ly changes in tumor size are better response predictors than 
other DCE derived parameters. Furthermore, some studies 
emphasized the analysis of intratumoral heterogeneity. Ac-
cording to one study, standard deviation (SD) of pixel val-
ues for Ktrans could allow for improved diagnostic accuracy 
for distinguishing breast cancer from benign lesions.11 Ac-
cordingly, a response group treated for locally advanced 
breast cancer exhibited significant reductions in SD of en-
hancement amplitude, demonstrating a more homogenous 
distribution after treatment.12 Although the results of several 
reports have been published, the predictability of DCE-de-
rived parameters are still debated and not standardized.
The aim of this study was to investigate the predictability 
of pretreatment values including DCE-MRI derived param-
eters (Ktrans, Kep and Ve), early changes in parameters (Ktrans, 
tumor volume), and heterogeneity (standard deviation of 
Ktrans) for radiation therapy responses via a human colorec-
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tumor heterogeneity, such as tumor necrosis. The largest 
length, width, and height of each tumor were measured 
from the T2-weighted images. Tumor volume was calculat-
ed by the formula of ellipsoid volume as follows:
π/6×L×W×H16
Where L was length, W was width, and H was the height 
of the tumor, respectively.
To evaluate the changes in the values of Ktrans and tumor 
volume in the early radiation therapy periods, we defined 
ratios of Ktrans, volume, and standard deviation as follows:
K1R=K1/K0
V1R=V1/V0
SD1R=SD1/SD0,
Where K0 values were of the 95th percentile of baseline 
Ktrans, V0 was the pretreatment tumor volume, and SD0 was 
the standard deviation of Ktrans at baseline. K1, V1, and SD1 
were values taken after the first radiation therapy.
Histological analysis
After performing DCE-MRI, the tumor was surgically ex-
cised from the right hind limb of the mice under ether anes-
thesia. The excised tumor was fixed with 10% formaldehyde 
solution and sliced in the transverse plane in 6 µm-thick 
slide sections, corresponding to the MR images. Histologi-
cal analysis of the tumor was performed with hematoxylin 
and eosin staining to identify tumor necrosis and to evalu-
ate tumor responses. Histological slides were scanned with 
a digital virtual microscope (Dotslide, Olympus, Hamburg, 
Germany). The outer tumor border and tumor necrosis were 
manually circumscribed using Image J software (NIH, 
Bethesda, MD, USA). Then the total pixel area of both the 
whole tumor and the necrotic region was automatically cal-
culated. Histological necrotic fraction (NF) was defined by 
dividing the total pixel area of necrosis by the total pixel 
area within the tumor border. A “good response” was clas-
sified for tumors exhibiting a NF greater than 0.4.17
 
RESULTS
 
Serial changes in the 95th percentile values for Ktrans, Kep, 
Ve, and tumor volume during radiation therapy were sum-
marized in Table 1. While tumors with an NF of less than 
0.4 were classified as demonstrating a poor response, 
mouse 3 with an NF of 0.49 was exceptionally classified as 
demonstrating a poor response, because a separate adjacent 
tumor had continuously grown after the first radiation ther-
prone in a plastic holder and connected to a mask carrying 
inhaled anesthetic to restrict movement. The mice were ini-
tially anesthetized with 4% isoflurane inhalation, and anes-
thesia was maintained with 2% isoflurane in a mixture of 1 
L/min of 100% oxygen. The tail vein was cannulated for in-
travenous access of MR contrast.
A transverse T2-weighted turbo spin echo sequence [repe-
tition time (TR)/echo time (TE), 4930/128 msec; echo train 
length, 25; one signal acquired; matrix, 114×192] was per-
formed with a section thickness of 1.0 mm, with an intersec-
tion gap of 0.12 mm and a flip angle of 160°. The field of 
view was 35×60 mm to cover the tumor completely (20 sec-
tions). T1 mapping was obtained using two variable flip an-
gle acquisitions. Two precontrast T1 weighted measure-
ments (3D VIBE; TR/TE, 8.32/2.29; matrix, 90×128) with 
different flip angles (2°, 15°) were performed with a section 
thickness of 1.04 mm (20 sections) and a field of view of 
50×50 mm. This was followed by the dynamic contrast en-
hanced series using the TWIST sequence (TR/TE, 5.81/2.42; 
flip angle, 12°; other parameters were the same as the pre-
contrast scan).
For the entire volume of 20 sections, the acquisition time 
was 6.2 seconds with a single signal acquired. This se-
quence was applied continuously for 60 measurements. Af-
ter the first five measurements, an intravenous bolus injec-
tion of gadopentetate dimeglumine (Magnevist; Schering, 
Erlangen, Germany) at a concentration of 0.05 mmol/mL 
was administered manually at a dose of 0.3 mmol/kg over 
the maximum period of 5 seconds.
On completion of the study, data were transferred to an 
image processing workstation (Leonardo; Siemens Health-
care sector, Erlangen, Germany) and analyzed using Tissue 
4D software (Siemens Healthcare sector, Erlangen, Germa-
ny). The dynamic data were fitted pixel by pixel to a phar-
macokinetic model described by Tofts,7,13 generating the 
transfer constant value, indicated by the symbol Ktrans (per 
second). 
Image analysis and measurement 
Regions of interests were outlined on each MRI. Software 
generated values for Ktrans, Kep, and Ve in each pixel and color 
maps for Ktrans pixel values. We selected values in the 95th 
percentile of distribution for each variable as being repre-
sentative of quantitative parameters rather than the maxi-
mum, because the former was suggested to reduce motion 
induced errors, specifically in the periphery of a tumor.14,15 
We avoided mean values because they did not reflect the 
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DISCUSSION
Over the past few years, CCRT or radiation therapy has been 
increasingly used to treat malignant neoplasms including rec-
tal cancer.18 Tumor vascularity and oxygenation status have 
long been advocated as important factors that influence tu-
mor responses to radiation therapy.5 DCE-MRI combined 
with pharmacokinetic modeling has emerged as a promising 
noninvasive imaging technique for evaluating tumor micro-
vasculature.6 Accordingly, previous studies suggested several 
DCE-MRI parameters for which to predict responses to radi-
ation therapy in rectal cancer as well as other tumors. The 
most representative DCE-MRI derived parameter is the 
transfer constant, Ktrans. However, the DCE-MR derived pa-
rameter Ktrans is still controversial as a biomarker for which to 
evaluate radiation therapy. de Vries, et al.19 reported that 
high initial perfusion index (PI) value correlated with great-
er node down staging for radiation therapy in rectal tumor.8 
Meanwhile, Sahani, et al.20 reported that initial high blood 
flow (BF) was negatively correlated with radiation therapy 
responses. They obtained BF as the representative parame-
apy (Fig. 1).
The good response group (mice #1, 2) showed higher 
pretreatment Ktrans than the poor response group (mice #3, 
4, 5). Two of the three mice in the poor response group (mice 
#4, 5) showed higher pretreatment Kep than those in the 
good response group (3.04, 1.67 vs. 0.89, 0.61). Two of the 
three mice in the poor response group (mice #3, 4) showed 
lower pretreatment Ve than those in the good response 
group (0.55, 0.42 vs. 0.61, 0.81). Two of the three mice in 
the poor response group (mice #3, 5) showed lower pre-
treatment volume than those in the good response group 
(270, 72 vs. 594, 1183) (Fig. 2). All the mice in the good re-
sponse group showed marked reductions in Ktrans and SD 
value after the first radiation. Two of the three mice (mice 
#3, 4) in the poor response group showed increased Ktrans 
(K1R=1.50, 2.32 for mice #3, 4) and SD value (SD1R=2 for 
both mice) after the first radiation therapy (Fig. 3). All tu-
mors showed increased volume after the first radiation ther-
apy. However, two of the three mice in the poor response 
group (mice #3, 5) showed greater volume increments than 
those in the good response group (V1R=2.13, 2.78 for #3, 5 
vs. 1.73, 1.33 for #1, 2).
Table 1. Sequential Changes in Quantitative DCE MRI Parameters during the Radiation Therapy
No.
Ktrans (sec-1) Kep (sec-1) Ve Tumor volume (mm3)
NF
Res-
ponseBase-
line
RT
K1R SD1R
Base-
line
RT Base-
line
RT Base-
line
RT
V1R
1st 2nd 3rd 1st 2nd 3rd 1st 2nd 3rd 1st 2nd 3rd 
1 0.26 0.09 0.02 0.11 0.35 0.44 0.89 10.5 2.26 3.53 0.61 0.55 0.14 0.65 1183 2048 2160 2618 1.73 0.51 G
2 0.29 0.14 0.13 0.13 0.48 0.56 0.61 0.38 0.37 0.55 0.81 0.71 0.70 0.57   594   792 1020 1400 1.33 0.46 G
3 0.11 0.17 0.22 0.16 1.50 2 0.77 0.41 0.74 0.89 0.55 0.79 0.80 0.61   270   576   832 1224 2.13 0.49   P*
4 0.05 0.12 0.16 0.05 2.32 2 3.04 0.51 0.59 5.81 0.42 0.57 0.66 0.37 1176 1360 2167 3240 1.15 0.38 P
5 0.08 0.02 0.13 0.21 0.25 0.33 1.67 6.20 1.64 4.32 0.70 0.06 0.74 0.67     72   200   507   539 2.78 0.24 P
RT, radiation therapy; DCE-MRI, dynamic contrast-enhanced magnetic resonance imaging.
K1R: ratio of Ktrans; SD1R: ratio of the standard deviation of Ktrans; V1R: ratio of the tumor volume after 1st radiation therapy to the baseline value, respectively.
NF (necrosis factor) is defined by dividing the total pixel area of necrosis by the total pixel area within the tumor border. 
G: good response, NF>0.4; P: poor response, NF≤4.
*Exceptionally assigned to the poor response group due to adjacent outgrowth of tumor.
Fig. 1. An exceptional case, mouse #3, was assigned to the poor response group although it showed a large area of necrosis (NF=0.49). (A) Serial DCE-MRI 
with color mapping shows the change in Ktrans. Pretreatment Ktrans showed a relatively low value (0.11). Ktrans increased after the first radiation therapy 
(K1R=1.51). Red color represents the higher value of Ktrans and blue color represents the lower value. An outgrowing tumor was identified after the first radia-
tion therapy (arrow). (B) H&E staining of the newly grown tumor, which separated from the main mass, showed rare necrosis. The original magnification is 
×2. The red line indicates the tumor border and the blue line indicates the area of necrosis. NF, necrotic fraction; H&E, hematoxylin and eosin.
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A B
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utes. Different types of imaging modalities, mathematic 
models, scan times, and post processing methods might ex-
plain the previous inconsistent results. Although our results 
showed that the responder group had a marked higher Ktrans 
value at baseline scanning, the results should be carefully 
interpreted because our sample size was too small and we 
ter for their model using perfusion CT technique with the 
Johnson and Wilson model during 45 seconds of scan time. 
While De Vries, et al.19 obtained PI value, which was 
shown to be associated with contrast extraction fraction as 
well as with perfusion using T1 dynamic contrast enhanced 
MRI technique with semi-quantitative analysis over 4 min-
Fig. 2. Comparison of quantitative parameters between the good and the poor response groups upon baseline imaging. (A) Ktrans, (B) Kep, (C) Ve, (D) pretreat-
ment tumor volume.
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Fig. 3. Comparison of Ktrans between the good and the poor response groups after the 1st radiation therapy. (A) Early changes in Ktrans and (B) early changes 
in standard deviation for Ktrans (SD). The y-axis represents the ratio of the value after the 1st radiation therapy to the pretreatment value. The horizontal solid 
line at the ratio of 1 represents no change within the interval.
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tic accuracy.11 Change in histogram heterogeneity has been 
reported in patients with rectal cancer after radiation thera-
py.27 Changes in tumor size were also previously suggested 
as a strong predictor of responses.10 In this study, good re-
sponders tended to show smaller volume increments than 
poor responders. However, tumor size change is not a perfect 
method for assessing the response of a tumor to treatment, as 
edema and necrosis refrain from measuring the exact tumor 
burden. For example, although mice #2 showed a good re-
sponse and marked reduction in Ktrans, tumor size masked the 
real tumor burden due to internal necrosis (Fig. 4).
This study has several limitations. First, fractionated dos-
es of radiation therapy and intervals between the fractionat-
ed doses might not be optimized to suppress endothelial 
cell proliferation. Second, though CCRT is widely used in 
the treatment of advanced colorectal cancer, our results 
were limited to radiation therapy.
In summary, the good response to radiation therapy group 
in a DLD-1 colon cancer xenograft mouse model exhibited 
higher pretreatment Ktrans and early reductions in Ktrans. Also, 
the distribution pattern of Ktrans in the early period of radia-
used dynamic contrast enhanced MRI with Tofts two com-
partment model over one minute. Our results might support 
the hypothesis that the permeable vasculature may provide 
better oxygenation and showed efficient radiation sensitivi-
ty.22 In addition, the good response to treatment group tend-
ed to exhibit lower Kep and higher Ve. Some studies report-
ed that the initial values of Kep and Ve might predict 
responses to radiation therapy.23-25 However, their use re-
mains highly debated and is not yet wholly established. Al-
though Kep also reflects vessel density, perfusion, and per-
meability, it proved to be not as sensitive to tumor 
oxygenation as Ktrans in this study. However, Kep may have 
been confounded by interstitial volume fraction (Ve) in the 
necrotic area.7
Early reductions in Ktrans among good responders are in 
agreement with previous studies,8,26 potentially indicating 
loss of immature tumor vessels. The good responders also 
showed early reductions in SD of Ktrans, demonstrating a 
more homogenous distribution. Distributions of variables, 
such as SD, add further information for which to distin-
guish malignancy from benign disease to improve diagnos-
Fig. 4. A representative case of good response in mouse #2. (A) Serial DCE-MRI with color mapping shows higher pretreatment Ktrans (0.29) and marked reduc-
tion in Ktrans after the first radiation therapy (K1R=0.47). (B) H&E staining of the corresponding section in mouse #2. The original magnification is ×2. Necrosis is 
identified in the center of the tumor. The red line indicates the tumor border and the blue line indicates the area of necrosis. The necrosis factor was 0.46. 
Histogram shows the heterogeneous distribution of Ktrans at baseline with an SD of 0.09 (C) and the homogenous distribution of Ktrans with an SD of 0.05 after the 
first radiation therapy (D). DCE-MRI, dynamic contrast-enhanced magnetic resonance imaging; SD, standard deviation; H&E, hematoxylin and eosin.
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